Hydrodistention Articles

To investigate whether the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ICPI) is efficacy measure tool for interstitial Cystitis (IC) treatment with hydrodistention (HD) and bladder training (BT).

To assess the impact of multiple (two or more) bladder hydrodistentions (HODs) on anesthetic BC in a large cohort of IC/BPS patients. Urinary bladder hydrodistention (HOD) under anesthesia is a third line therapeutic approach used to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS).

The aim of this study was to investigate the clinical characteristics of nocturia in patients with interstitial cystitis (IC), and the effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia.

Objective Ketamine-associated cystitis (KAC) has been described in a few case reports, but its treatment in a relatively large number of patients has not been documented. This study aimed to describe our experience of treatment of 36 patients with KAC.

INTRODUCTION - For bladder pain syndrome (BPS) refractory to conservative treatment, the European guidelines consider bladder hydrodistention (HD) under anaesthesia and the injection of Onabotulinumtoxin A (OnabotA) jointly.

A botulinum toxin A (BoNT-A) intravesical injection can improve the symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS). Patients with IC/BPS have different clinical characteristics, urodynamic features, and cystoscopic findings.

To evaluate whether hydrodistention with fulguration of Hunner lesions (HD/FUL) plus maintenance dimethyl sulfoxide (DMSO) therapy prolongs the recurrence-free time in patients with Hunner type interstitial cystitis (IC).

We compared the therapeutic efficacy of transurethral resection (TUR) alone to that of TUR combined with therapeutic hydrodistention in patients with ulcerative interstitial cystitis (IC).

The study subjects were newly diagnosed IC patients 44 female patients who underwent TUR to treat ulcerative IC and who were available for follow-up, without recurrence of disease for 12 months.